What Will Happen to Emergent BioSolutions Inc. (EBS) Next? The Stock Just Reaches 52-Week High

March 20, 2018 - By Darrin Black

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.12, from 1.57 in 2017Q2. It improved, as 11 investors sold Emergent BioSolutions Inc. shares while 48 reduced holdings. 34 funds opened positions while 66 raised stakes. 33.90 million shares or 1.32% less from 34.36 million shares in 2017Q2 were reported.
Systematic Financial Lp owns 41,545 shares for 0.03% of their portfolio. Yorktown Mngmt And Rech has 8,600 shares. Loomis Sayles Com Lp stated it has 871 shares or 0% of all its holdings. Citadel Advsr Lc owns 16,977 shares for 0% of their portfolio. Ameriprise Inc accumulated 278,059 shares or 0.01% of the stock. First Trust Advisors L P accumulated 0% or 35,762 shares. Eagle Asset Inc has invested 0.06% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Us Bancorp De holds 37,498 shares. Victory Capital Management holds 4,715 shares. Ameritas Inv Prtnrs Inc holds 0.01% or 2,888 shares in its portfolio. Credit Suisse Ag invested 0% in Emergent BioSolutions Inc. (NYSE:EBS). Nationwide Fund Advsr invested in 25,881 shares. Guggenheim Capital Lc holds 0.03% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS) for 364,277 shares. Envestnet Asset Management Incorporated reported 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Manufacturers Life Insurance The reported 649,220 shares.

Since September 27, 2017, it had 0 buys, and 10 insider sales for $7.69 million activity. Abdun-Nabi Daniel sold 15,000 shares worth $598,770. Havey Adam sold $311,458 worth of stock. The insider Hauer Jerome M sold 7,729 shares worth $391,787. The insider El-Hibri Fuad sold $2.00 million.

The stock of Emergent BioSolutions Inc. (NYSE:EBS) hit a new 52-week high and has $55.41 target or 4.00 % above today’s $53.28 share price. The 8 months bullish chart indicates low risk for the $2.64 billion company. The 1-year high was reported on Mar, 20 by Barchart.com. If the $55.41 price target is reached, the company will be worth $105.48M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 2.30% or $1.2 during the last trading session, reaching $53.28. About 179,926 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has declined 23.64% since March 20, 2017 and is downtrending. It has underperformed by 40.34% the S&P500.

Analysts await Emergent BioSolutions Inc. (NYSE:EBS) to report earnings on May, 3. They expect $0.30 earnings per share, up 3.45 % or $0.01 from last year’s $0.29 per share. EBS’s profit will be $14.85 million for 44.40 P/E if the $0.30 EPS becomes a reality. After $0.74 actual earnings per share reported by Emergent BioSolutions Inc. for the previous quarter, Wall Street now forecasts -59.46 % negative EPS growth.

Emergent BioSolutions Inc. (NYSE:EBS) Ratings Coverage

Among 5 analysts covering Emergent Biosolutions (NYSE:EBS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Emergent Biosolutions has $60 highest and $3300 lowest target. $45.83’s average target is -13.98% below currents $53.28 stock price. Emergent Biosolutions had 9 analyst reports since August 10, 2015 according to SRatingsIntel. Chardan Capital Markets initiated it with “Buy” rating and $47 target in Friday, April 15 report. On Monday, August 10 the stock rating was upgraded by Zacks to “Hold”. The firm has “Outperform” rating by Wells Fargo given on Friday, February 19. Cowen & Co maintained Emergent BioSolutions Inc. (NYSE:EBS) rating on Friday, July 14. Cowen & Co has “Hold” rating and $3300 target. The rating was initiated by Singular Research on Monday, March 28 with “Buy”. Singular Research maintained it with “Buy” rating and $40 target in Tuesday, June 28 report. The rating was maintained by Singular Research with “Buy” on Tuesday, February 27.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. The company has market cap of $2.64 billion. The Company’s products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. It has a 31.23 P/E ratio. The companyÂ’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.